Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SMMT
- Price
- 23.24
- Stock movement up
- +3.09 (15.34%)
- Company name
- Summit Therapeutics PLC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 17.14B
- Ent value
- 17.11B
- Price/Sales
- -
- Price/Book
- 39.14
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 5.48%
- 1 year return
- 481.00%
- 3 year return
- 116.50%
- 5 year return
- 57.74%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SMMT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 39.14 |
| EV to Sales | -72806.16 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 737.45M |
| EPS (TTM) | -0.27 |
| FCF per share (TTM) | -0.16 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | -235.00K |
| Gross profit (TTM) | -907.00K |
| Operating income (TTM) | -181.48M |
| Net income (TTM) | -196.68M |
| EPS (TTM) | -0.27 |
| EPS (1y forward) | -0.29 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 385.96% |
| Operating margin (TTM) | 77226.38% |
| Profit margin (TTM) | 83693.19% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 93.78M |
| Net receivables | 660.00K |
| Total current assets | 490.29M |
| Goodwill | 1.99M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 8.24M |
| Total assets | 502.85M |
| Accounts payable | 3.25M |
| Short/Current long term debt | 32.50M |
| Total current liabilities | 59.01M |
| Total liabilities | 64.93M |
| Shareholder's equity | 437.92M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -112.74M |
| Capital expenditures (TTM) | 126.84K |
| Free cash flow (TTM) | -112.87M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -44.91% |
| Return on Assets | -39.11% |
| Return on Invested Capital | -42.19% |
| Cash Return on Invested Capital | -24.21% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 20.24 |
| Daily high | 23.31 |
| Daily low | 20.16 |
| Daily Volume | 6.64M |
| All-time high | 31.93 |
| 1y analyst estimate | 32.81 |
| Beta | -0.92 |
| EPS (TTM) | -0.27 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 29 Apr 2025 |
Downside potential
Loading...
Downside potential data
| SMMT | S&P500 | |
| Current price drop from All-time high | -27.22% | -12.89% |
| Highest price drop | -95.75% | -56.47% |
| Date of highest drop | 1 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -59.34% | -11.07% |
| Avg time to new high | 126 days | 12 days |
| Max time to new high | 1758 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
17.14B
Marketcap category
Large-cap
Description
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Employees
105
Website
Investor relations
-
SEC filings
CEO
Glyn Owain Edwards
Country
USA
City
Abingdon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page